456 results on '"Malaise, M."'
Search Results
2. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
3. Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers
4. POS0919 [18F] POSITRON EMISSION COMPUTED TOMOGRAPHY ([18F] FDG PET/CT) IS ABLE TO PREDICT ULTRASOUND-DEFINED REMISSION IN RHEUMATOID ARTHRITIS
5. POS0504 COMPARISON BETWEEN « SYSTEMATIC » VERSUS « RECOMMENDATION-BASED » VERTEBRAL FRACTURE ASSESSMENT REALIZATION DURING DUAL ENERGY X-RAY ABSORPTIOMETRY EXAMINATION
6. OP0129 EFFECTIVENESS OF COBRA-SLIM WITH OR WITHOUT EARLY ACCESS TO A TEMPORARY 6-MONTH COURSE OF ETANERCEPT IN EARLY RA: PRIMARY OUTCOME OF THE 2-YEAR, PRAGMATIC, RANDOMISED CARERA2020 TRIAL
7. Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study
8. Comparison of serum fractionation methods by data independent label-free proteomics
9. Réalisation « systématique » ou « basée sur les recommandations » d’une radiographie du rachis dorsolombaire (Vertebral Fracture Assessment) lors d’un examen de densitométrie osseuse ?
10. Airflow obstruction as a marker of prognosis in rheumatoid arthritis
11. Plasma-derived exosomal miRNAs as non-invasive biomarkers for lung involvement in systemic sclerosis
12. Évolution de la densité minérale osseuse, et de la micro-architecture osseuse après transplantation rénale : résultats à 3 mois d’une étude de cohorte prospective
13. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
14. AB0169 EARLY REMISSION AT 6 MONTHS AS A PREDICTOR OF LONGTERM REMISSION IN NEW ONSET RHEUMATOID ARTHRITIS
15. La rémission précoce à 6 mois comme prédicteur de la rémission à long terme dans la polyarthrite rhumatoïde débutante
16. CEMIP régule l’inflammation, l’hyperplasie et la fibrose de la membrane synoviale arthrosique
17. Influence des glucocorticoïdes sur les caractéristiques de la sénescence cellulaire dans les fibroblastes synoviaux d’origine arthrosique
18. Imagerie optique par HandScan dans la métrologie de la polyarthrite rhumatoïde : étude des capacités de prédiction de la rémission clinique et échographique
19. PE.Lu-108 - Caractéristiques initiales et résultats préliminaires du suivi de la cohorte CAP48 Polyarthrite Rhumatoïde débutante
20. P.07 - Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale au stade préfracturaire : étude randomisée
21. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium
22. THE ROLE OF RORγT IN T17-MEDIATED ALLOGRAFT REJECTION: 244
23. Les recommandations « ostéoporose » SFR 2018 identifient une population de polyarthrites rhumatoïdes avec une activité plus élevée et une micro-architecture osseuse (Hr-pQCT) moins bonne : étude de l’influence de la maladie sur les paramètres osseux
24. S-Coll2-1 and s-Coll2-1NO2 sont des marqueurs de la sévérité et de la progression de l’arthrose du genou : résultats de l’étude PRODIGE
25. Traiter un cancer pulmonaire avec une dermatomyosite « paranéoplasique » associée par un inhibiteur des points de contrôle immunitaire : une fausse bonne idée ?
26. Inflammatory profile of induced sputum composition in systemic sclerosis: a comparison with healthy volunteers
27. FRI0405 CARTILAGE BIOMARKERS S-COLL2-1 AND S-COLL2-1NO2 ARE HELPFUL IN IDENTIFYING KNEE OSTEOARTHRITIS PATIENTS AT RISK OF DISEASE WORSENING
28. Proteins involved in the endoplasmic reticulum stress are key players in synovitis of osteoarthritis, chronic pyrophosphate arthropathy and rheumatoid arthritis, and correlate with the histological inflammatory score
29. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study
30. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip
31. The use of sandimmun® (cyclosporin A) in severe refractory rheumatoid arthritis: The Belgian experience
32. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
33. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: Exploring decision rules for clinical utility
34. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: Prevalence of inflammation in osteoarthritis
35. Timing of DAS28 in infliximab therapy
36. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
37. EULAR report on the use of ultrasonography in painful knee osteoarthritis
38. Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohnʼs disease patients
39. Rapid improvement of bone metabolism after infliximab treatment in Crohnʼs disease
40. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
41. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
42. Evidence that the interaction between circulating IgA and fibronectin is a normal process enhanced in primary IgA nephropathy
43. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
44. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
45. Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma
46. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
47. Relationship between bone mass density and tensile strength of the skin in women
48. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis
49. Cytokine production from peripheral whole blood in atopic and nonatopic asthmatics[colon] relationship with blood and sputum eosinophilia and serum IgE levels
50. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.